Bacterial genome editing

Background of bacterial genome editing

• Colibactin is a genotoxin synthesized by Escherichia coli that induces DNA damage that can lead to gene mutations, chromosomal instability, and senescence.
• Colibactin-producing E. coli strains are associated with cancerous and precancerous colorectal tissues and are suspected of promoting colorectal carcinogenesis
• Polyamines are highly abundant in cancer tissue

Objectives of the model

• To inactivate genes required for the synthesis of spermidine.
• To determine the roles of polyamine spermidine in colibactin genotoxic activity

Our approach at Vibiosphen 

• Inactivate the genes speB, speC, speE, and speG, required for the synthesis of spermidine by using the lambda Red recombinase method

• Provide in vitro data on the production of colibactin by each above mutant through bacterium-host cell interactions

Outcomes of bacterial genome editing model

• New interplay between the synthesis of the genotoxin colibactin and the polyamine spermidine
• New perspective on the role of this metabolite in the pathogenicity of colibactin-producing E. coli strains in colorectal cancer.

Why Choose Vibiosphen?

• Proven expertise in preclinical research
• Flexible and customized study designs adapted to sponsor requirements (see downloads available as example) 
• Advanced facilities to ensure reliable and reproducible results (BSL2 and BSL3) 
• Strong collaborations with pharmaceutical companies, biotech firms, and academic partners

Vibiosphen combines scientific excellence with industry know-how to deliver actionable preclinical data that drive innovation in infectious disease therapeutics.
 

Contact Us

If you are developing new treatments or vaccines, Vibiosphen can help accelerate your research.
Contact us today to discuss your project and explore how our Pharmacokinetics models can support your development strategy. 
We will be pleased to facilitate your project by providing a customized study design to your project objectives.